Treatment characteristics for studied WM patients stratified by MYD88 and NS and FS CXCR4 mutation status
| . | MYD88WTCXCR4WT . | MYD88L265PCXCR4WT . | MYD88L265PCXCR4WHIM/FS . | MYD88L265PCXCR4WHIM/NS . | P . |
|---|---|---|---|---|---|
| n | 15 | 109 | 24 | 26 | |
| Number of therapies | 2 (0-8) | 2 (0-7) | 1 (0-4) | 2 (1-8) | – |
| Rituximab | 11 (68.8%) | 89 (81.7%) | 18 (75.0%) | 22 (84.6%) | – |
| Alkylator | 7 (43.8%) | 63 (57.8%) | 13 (54.2%) | 13 (50.0%) | – |
| Nucleoside analog | 3 (18.8%) | 20 (18.4%) | 2 (8.3%) | 3 (11.5%) | – |
| Proteasome inhibitor | 6 (37.5%) | 41 (37.6%) | 4 (17.0%) | 14 (53.9%) | – |
| Immunomodulatory | 1 (6.3%) | 6 (5.5%) | 0 (0%) | 2 (7.7%) | – |
| . | MYD88WTCXCR4WT . | MYD88L265PCXCR4WT . | MYD88L265PCXCR4WHIM/FS . | MYD88L265PCXCR4WHIM/NS . | P . |
|---|---|---|---|---|---|
| n | 15 | 109 | 24 | 26 | |
| Number of therapies | 2 (0-8) | 2 (0-7) | 1 (0-4) | 2 (1-8) | – |
| Rituximab | 11 (68.8%) | 89 (81.7%) | 18 (75.0%) | 22 (84.6%) | – |
| Alkylator | 7 (43.8%) | 63 (57.8%) | 13 (54.2%) | 13 (50.0%) | – |
| Nucleoside analog | 3 (18.8%) | 20 (18.4%) | 2 (8.3%) | 3 (11.5%) | – |
| Proteasome inhibitor | 6 (37.5%) | 41 (37.6%) | 4 (17.0%) | 14 (53.9%) | – |
| Immunomodulatory | 1 (6.3%) | 6 (5.5%) | 0 (0%) | 2 (7.7%) | – |
–, not significant.